Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Genes & Development|June 21, 2018
Polycystic kidney disease: a Hippo connectionShenghong Ma, Kun-Liang GuanAnnual Review of Biochemistry|December 20, 2018
The Hippo Pathway: Biology and PathophysiologyShenghong Ma, Zhipeng Meng, Rui Chen, et al.Cancer Cell|March 23, 2013
R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesisDan Ye, Shenghong Ma, Yue Xiong, et al.Nature Cell Biology|December 4, 2019
STRIPAK integrates upstream signals to initiate the Hippo kinase cascadeRui Chen, Ruiling Xie, Zhipeng Meng, et al.Nature Cell Biology|January 4, 2020
Publisher Correction: STRIPAK integrates upstream signals to initiate the Hippo kinase cascadeRui Chen, Ruiling Xie, Zhipeng Meng, et al.Nature Communications|September 22, 2023
YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasisZhengming Wu, Junhui Su, Fu-Long Li, et al.Nature Communications|February 26, 2022
Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancerShenghong Ma, Tracy Tang, Gary Probst, et al.The Journal of Biological Chemistry|May 27, 2018
The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cellSteven W Plouffe, Kimberly C Lin, Jerrell L Moore, et al.Cell Reports|October 26, 2018
Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma SellsMehmet G Badur, Thangaselvam Muthusamy, Seth J Parker, et al.Oncotarget|April 1, 2015
D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growthShenghong Ma, Bowen Jiang, Wanglong Deng, et al.Pageof 2